RB1 loss overrides PARP inhibitor sensitivity driven by RNASEH2B loss in prostate cancer
暂无分享,去创建一个
Z. Szallasi | A. Kibel | K. Mouw | L. Jia | L. Zou | H. Azuma | Z. Sztupinszki | C. Miao | T. Tsujino | Tomoaki Takai | T. Tsutsumi | Zengjun Wang | Fu Gui | L. Zou
[1] K. Knudsen,et al. RB/E2F1 as a master regulator of cancer cell metabolism in advanced disease. , 2021, Cancer discovery.
[2] S. West,et al. Targeting the nucleotide salvage factor DNPH1 sensitizes BRCA-deficient cells to PARP inhibitors , 2021, Science.
[3] J. Gillet. Faculty Opinions recommendation of The great escape: tumour cell plasticity in resistance to targeted therapy. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.
[4] G. Mills,et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models , 2020, Nature Communications.
[5] Michael D. Nyquist,et al. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. , 2020, Cell reports.
[6] F. Saad,et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2020, The New England journal of medicine.
[7] T. Aittokallio,et al. SynergyFinder 2.0: visual analytics of multi-drug combination synergies , 2020, Nucleic Acids Res..
[8] Y. Kawasawa,et al. Identification of regulators of poly-ADP-ribose polymerase inhibitor response through complementary CRISPR knockout and activation screens , 2019, Nature Communications.
[9] P. Kantoff,et al. Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression , 2019, Clinical Cancer Research.
[10] N. Tunariu,et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial , 2019, The Lancet. Oncology.
[11] Kejiao Li,et al. A Genetic Map of the Response to DNA Damage in Human Cells , 2019, Cell.
[12] F. D. de Sauvage,et al. The great escape: tumour cell plasticity in resistance to targeted therapy , 2019, Nature Reviews Drug Discovery.
[13] E. Antonarakis,et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. , 2019, European urology.
[14] A. Bryce,et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses , 2019, Annals of Oncology.
[15] A. Sboner,et al. PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer , 2019, Clinical Cancer Research.
[16] A. Kibel,et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function , 2019, Proceedings of the National Academy of Sciences.
[17] M. Loda,et al. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer. , 2019, European urology.
[18] Yi Mi Wu,et al. Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.
[19] M. Gleave,et al. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. , 2019, European urology.
[20] B. Leiby,et al. PARP‐1 regulates DNA repair factor availability , 2018, EMBO molecular medicine.
[21] F. Demichelis,et al. RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate Cancer , 2018, Clinical Cancer Research.
[22] G. Sauter,et al. 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer , 2018, Genes, chromosomes & cancer.
[23] M. Smolka,et al. ATR-mediated proteome remodeling is a major determinant of homologous recombination capacity in cancer cells , 2018, Nucleic acids research.
[24] Martin A. M. Reijns,et al. CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions , 2018, Nature.
[25] Yi Mi Wu,et al. The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.
[26] M. Rubin,et al. Differential impact of RB status on E2F1 reprogramming in human cancer , 2017, The Journal of clinical investigation.
[27] H. Kurumizaka,et al. RFWD3-Mediated Ubiquitination Promotes Timely Removal of Both RPA and RAD51 from DNA Damage Sites to Facilitate Homologous Recombination. , 2017, Molecular cell.
[28] Tero Aittokallio,et al. SynergyFinder: a web application for analyzing drug combination dose–response matrix data , 2017, Bioinform..
[29] S. Ramaswamy,et al. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells , 2017, Genes & development.
[30] Henry W. Long,et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.
[31] M. Rubin,et al. SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.
[32] N. Dyson. RB1: a prototype tumor suppressor and an enigma , 2016, Genes & development.
[33] R. D. de Bruin,et al. Sustained E2F-Dependent Transcription Is a Key Mechanism to Prevent Replication-Stress-Induced DNA Damage , 2016, Cell reports.
[34] Alan Ashworth,et al. BRCAness revisited , 2016, Nature Reviews Cancer.
[35] Wei Yuan,et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.
[36] Jessica L. Boisvert,et al. Distinct but Concerted Roles of ATR, DNA-PK, and Chk1 in Countering Replication Stress during S Phase. , 2015, Molecular cell.
[37] Lawrence D. True,et al. Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.
[38] P. Fortina,et al. The Retinoblastoma Tumor Suppressor Modulates DNA Repair and Radioresponsiveness , 2014, Clinical Cancer Research.
[39] Martin A. M. Reijns,et al. Ribonuclease H2 in health and disease. , 2014, Biochemical Society transactions.
[40] S. Vowler,et al. HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network , 2014, EMBO molecular medicine.
[41] Y. Pommier,et al. Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib , 2013, Molecular Cancer Therapeutics.
[42] Wennuan Liu,et al. Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma , 2013, Clinical Cancer Research.
[43] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[44] D. Terrian,et al. p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3 , 2012, Cell cycle.
[45] Y. Pommier,et al. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. , 2012, Cancer research.
[46] L. Jia,et al. Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions , 2012, Nucleic acids research.
[47] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[48] S. Detti,et al. Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. , 2012, Clinical genitourinary cancer.
[49] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[50] Thomas Helleday,et al. The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings , 2011, Molecular oncology.
[51] A. Ashworth,et al. A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.
[52] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[53] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[54] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[55] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[56] C. Simbulan-Rosenthal,et al. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase , 2003, Oncogene.
[57] H. Frierson,et al. Deletion at 13q21 is associated with aggressive prostate cancers. , 2000, Cancer research.
[58] J. Nevins,et al. Role of E2F transcription factor in E1A-mediated trans activation of cellular genes , 1991, Journal of virology.
[59] David G Johnson,et al. Transcriptional and nontranscriptional functions of E2F1 in response to DNA damage. , 2012, Cancer research.
[60] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[61] A. Freeman,et al. Allelic imbalance at 13q14.2 approximately q14.3 in localized prostate cancer is associated with early biochemical relapse. , 2007, Cancer genetics and cytogenetics.
[62] N. Oppenheimer,et al. Structure and mechanism , 1989 .